CLINICAL_TRIALS
ClinicalTrials.gov record update
Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02991638
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:36:57.682479+00:00
- Published At
- 2018-04-12T00:00:00+00:00
- Record Updated At
- 2018-04-12
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Chronic Lymphocytic Leukemia", "Indolent B-cell Lymphomas", "Chronic Hepatitis B", "Lymphoma, Small Lymphocytic", "Mantle-Cell Lymphoma", "Waldenstrom\u0027s Macroglobulinaemia", "Follicular Lymphoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-04-12"- protocolSection.identificationModule.nctId
"NCT02991638"- protocolSection.identificationModule.officialTitle
"Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.